NA
Insider
Noubar Afeyan
DirectorNoubar Afeyan (Director) filed 4 Form 4 reports in the trailing twelve months (2 purchases, 2 sales), most often in GENB. Across 2 priced purchase filings, the average 21-session return was -4.2% from execution and -4.2% from disclosure (delay-adjusted; derived). The largest single filing was $75.0M of GENB (4,687,500 sh across 3 lots, as filed), executed Mar 2.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-4.2%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-4.2%
same 2 filings, from disclosure
Filings, ttm
4
2 buys · 2 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$151.1M
shares × price, as filed
Last traded
May 21
Filed May 22
Median ADV $1.0B across their filed names
Open performance→Volume by month
Buys $150.0M
Sells $1.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Not on file
2 filings
Sector per market data · by filing · past 12 months
Most traded names
GENB
GENB
GENB · 2 buys · 0 sells
2 filings
MRNARecent filings
MRNASALE
Moderna, Inc.
View filing →
$434K9,263 sh × $46.84
Exec May 21
Filed May 22 · 5:30 PM ET GENBPURCHASE Generate Biomedicines, Inc. View filing → $75.0M
4,687,500 sh across 3 lots
Exec Mar 2
Filed Mar 2 · 5:52 PM ET GENBPURCHASE Generate Biomedicines, Inc. View filing → $75.0M
4,687,500 sh across 3 lots
Exec Mar 2
Filed Mar 2 · 5:42 PM ET MRNASALE Moderna, Inc. View filing → $703K
23,853 sh × $29.49
Exec Dec 11 2025
Filed Dec 15 2025 · 5:30 PM ET